Nebivolol Treatment in Pediatric Heart Failure Patients


In contrast to adult heart failure, the pathophysiology of the development of myocardial dysfunction and heart failure in children is poorly understood. For example, traditional β-blocking agents have a clear benefit in the treatment of heart failure in adults but for pediatric patients, there is no demonstrated clinical benefit. To address this unmet need of this population, CU researchers - led by Dr. Brian Stauffer - have developed a method of treating heart failure in pediatric patients using a β1-selective adrenergic receptor antagonist such as Nebivolol. A benefit of using a more selective antagonist is minimal inhibition of the β2 receptor, which protects against cellular apoptosis and which is important for augmentation of muscle contractile function.


Download Summary Document Here:
For Information, Contact:
Mary Tapolsky
University of Colorado
Brian Stauffer
Carmen Sucharov
Shelley Miyamoto
Disease Areas:
For inquiries, email:     © 2024. All Rights Reserved. Powered by Inteum